Loading...
XSHE
002566
Market cap381mUSD
Jul 14, Last price  
8.26CNY
1D
1.85%
1Q
13.77%
Jan 2017
-35.47%
IPO
-37.09%
Name

Jilin Jian Yisheng Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
28.86
P/S
3.20
EPS
0.29
Div Yield, %
1.82%
Shrs. gr., 5y
—
Rev. gr., 5y
-2.62%
Revenues
854m
+2.85%
226,373,903267,837,384311,753,125414,884,408516,224,102528,925,262600,503,234643,896,712787,894,295819,598,117939,012,6281,034,442,376975,088,2001,012,748,483842,589,907877,929,541830,041,323853,664,904
Net income
95m
+14.00%
23,471,69336,109,52341,366,69761,128,77087,637,99096,484,10596,626,83087,319,04996,408,83010,911,48513,194,41160,069,57469,079,28276,598,73680,060,08596,020,34983,096,99494,732,729
CFO
209m
+43.38%
0020,497,435125,246,25550,725,273079,078,5930000270,654,341167,318,427210,871,994203,514,966215,100,714145,856,177209,130,115
Dividend
May 22, 20240.15 CNY/sh

Profile

Jilin Jian Yisheng Pharmaceutical Co., Ltd. manufactures and sells medicine, Chinese herbal medicine, cosmetics, and food products in China. It offers capsules, injections, tablets, granules, and other products; and Ginseng medicinal and bee products. Jilin Jian Yisheng Pharmaceutical Co., Ltd. was founded in 1997 and is based in Ji'an, China.
URL
http://www.yisheng-pharm.com/
IPO date
Mar 18, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
853,665
2.85%
830,041
-5.45%
Cost of revenue
568,384
658,090
Unusual Expense (Income)
NOPBT
285,281
171,951
NOPBT Margin
33.42%
20.72%
Operating Taxes
15,652
12,907
Tax Rate
5.49%
7.51%
NOPAT
269,630
159,044
Net income
94,733
14.00%
83,097
-13.46%
Dividends
(29,857)
(9,929)
Dividend yield
1.01%
0.37%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
470,433
433,721
Long-term debt
8,053
19,649
Deferred revenue
118,023
Other long-term liabilities
118,694
1
Net debt
(112,230)
50,264
Cash flow
Cash from operating activities
209,130
145,856
CAPEX
(35,772)
Cash from investing activities
1,768
Cash from financing activities
8,734
FCF
322,245
191,262
Balance
Cash
590,716
403,107
Long term investments
1
2
Excess cash
548,033
361,605
Stockholders' equity
1,357,516
1,455,619
Invested Capital
2,377,541
2,430,572
ROIC
11.22%
6.51%
ROCE
9.75%
6.16%
EV
Common stock shares outstanding
330,952
330,952
Price
8.90
9.88%
8.10
-10.40%
Market cap
2,945,469
9.88%
2,680,708
-10.40%
EV
2,932,496
2,825,422
EBITDA
334,208
216,222
EV/EBITDA
8.77
13.07
Interest
13,777
14,033
Interest/NOPBT
4.83%
8.16%